Anticancer drugs development

Johnson JR, Williams G, Pazdur R (2003) J Clin Oncol 21 1404 Dagher RN, Pazdur R (2004) The phase III clinical cancer trial. In Teicher BA, Andrews PA (eds) Anticancer drug development guide, 2nd edn. Humana Press, Totowa, NJ, p 401... 

Powis G (1991) Signalling targets for anticancer drug development. Trends Pharmacol Sci 12 188-194... 

Taxol was the most triumphant new anticancer drug developed in the last few decades. It resulted from a drive to screen thousands of synthesized compounds and plant extracts, financed by the National Cancer Institute (Georg et al. 1994, Suffness 1995, Goodman and Walsh 2001). Taxol is extracted from the bark of the Pacific yew tree, or Taxus brevifoli, found in the Pacific Northwest, and has been proven effective against intractable breast and ovarian cancers. It is now produced by semi-synthetic methods from the needles of the common ornamental tree English Yew, or Taxus baccata. We will discuss taxol in greater detail in Chapter 2. 

Gordon Rewcastle obtained his PhD in Organic Chemistry from the University of Auckland in 1978, and after post-doctoral study in the U.S., he joined the Auckland Cancer Society s Research Laboratory as a medicinal chemist in 1980. Since then has participated in a number of antibacterial and anticancer drug development projects, and is the author or co-author of over 100 scientific papers and patents in the anticancer area. In all, he has made significant contributions to the development of six of the eight anticancer drugs to have gone to clinical trial from the Auckland Cancer Centre. 

From Cancer Drug Discovery and Development Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response Edited by F. Irmocenti, DOT 10.1007/978-l-60327-088-5 I, Humana Press, Totowa, NJ... 

From Cancer Drug Discovery and Development Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response... 

Genomics and Pharmacogenomics IN Anticancer Drug Development AND Clinical Response... 

Cummings J, Ward TH, Greystoke A, et al. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008 153 646-656. 

Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006 66 3351-4. 

Kelland LR. Of mice and men values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004 40 827-36. 

Huang CC, Han CS, Yue XF, Shen CM, Wang SW, Wu FG, Xu B. Cytotoxity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People s Republic of China. J. Natl. Cancer Inst. 1983 71 841-847. 

Hoffman RM. Fertile seed and rich soil The development of clinically relevant models of human cancer by surgical orthotopic implantation of intact tissue. In Teicher BA, editor. Anticancer drug development guide Preclinical screening, clinical trials and approval. Totowa, NJ Humana Press 1997. p. 127-44. 

---